City Therapeutics
banner
citytx.bsky.social
City Therapeutics
@citytx.bsky.social
Leading the next-generation of RNAi trigger molecule engineering to develop a pipeline of disruptive medicines.
Excited to announce the submission of our CTA to the @mhragovuk.bsky.social to initiate a Phase 1 study of CITY-FXI, an investigational RNAi therapeutic targeting Factor XI w/ the potential to safely & effectively prevent blood clots without increasing bleeding risk. www.citytx.com/news/city-th...
November 10, 2025 at 1:08 PM
Honored to be named by LinkedIn as a Top 10 #LinkedInTopStartups of Boston in 2025! In the heart of Kendall Square, we’re building a place where careers & cutting-edge RNAi science can thrive. www.linkedin.com/pulse/linked...
October 29, 2025 at 3:33 PM
One year strong, from growing our team to building partnerships, our focus is unwavering to reshape the future of RNAi medicines. Here's to what's next!
October 8, 2025 at 3:20 PM
Check out City's Executive Chair, @jmaraganore.bsky.social presenting at Fierce Biotech Week 2025 this week, where he'll offer insights from his past and reflect on the evolving landscape of RNAi! www.fiercebiotechweek.com/event/fierce...
Featured Presentation: Building Alnylam and the Importance of Being Unreasonable | Fierce Biotech Week
www.fiercebiotechweek.com
October 7, 2025 at 1:40 PM
Exciting news from City! We’ve partnered with Biogen to develop select novel RNAi-based therapies leveraging our next-generation RNAi engineering technologies. Learn more: www.globenewswire.com/news-release...
May 27, 2025 at 11:46 AM
Excited to welcome Baisong Mei, M.D., Ph.D., as CMO, Anna O’Driscoll as CHRO, and Sara Nochur, Ph.D., as an independent board member! Their expertise in life sciences will help drive our next phase of growth. Learn more below and at: www.businesswire.com/news/home/20...
April 17, 2025 at 2:34 PM